Price
No data yet.
Social Signal Score
Analyst Ratings
37 analystsRevenue
$959.00MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kyle W. Gano
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,500
- Beta
- 0.38
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 6.71
Financials
Revenue
$959.00M+15038.1%Net Income
$144.40MEBITDA
$189.90MFree Cash Flow
$128.60MEPS (diluted)
$1.39Shares Outstanding (diluted)
104.20M+20.1%Operating Expenses
$766.40MCash & Debt
$389.80MReturn of Capital
$12.00MRevenue by Segment (annual)
$2.86BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.86B | $478.60M | $4.81 |
| 2024 | $2.36B | $341.30M | $3.40 |
| 2023 | $1.89B | $249.70M | $2.56 |
| 2022 | $1.49B | $154.50M | $1.61 |
| 2021 | $1.13B | $89.60M | $0.95 |
| 2020 | $1.05B | $407.30M | $4.37 |
| 2019 | $788.10M | $37.00M | $0.40 |
| 2018 | $451.20M | $21.11M | $0.22 |
| 2017 | $161.63M | $-142.54M | $-1.62 |
| 2016 | $15.00M | $-141.09M | $-1.63 |
| 2015 | $19.77M | $-88.93M | $-1.05 |
| 2014 | $0.00 | $-60.54M | $-0.81 |
| 2013 | $2.92M | $-46.09M | $-0.69 |
| 2012 | $53.14M | $5.03M | $0.08 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NBIX's reported EPS growth of 37.5% a year over 13 years. Historical EPS growth of 37% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $17.86
- Implied price
- $517.92
- Return from $143.18
- 29.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $257.50 — today's price is already 44.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| 20.0% | 11.9% | 15.9% | 19.4% | 22.5% | 25.3% |
| 25.0% | 16.6% | 20.7% | 24.3% | 27.6% | 30.6% |
| 30.0% | 21.2% | 25.5% | 29.3% | 32.7% | 35.8% |
| 35.0% | 25.9% | 30.4% | 34.3% | 37.8% | 41.0% |
| 40.0% | 30.6% | 35.2% | 39.3% | 42.9% | 46.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60-22.58%Social Signal Score
Mentions (17)
- Newsprnewswire.com·6d ago·Positive
…id retention, hyperglycemia, hirsutism and hypertrichosis — during VYKAT XR treatment SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and expanding clinical and real-world evidence for VYKAT® XR (diazoxide choline) extended-release tablets will be presented at the Foundation for Prader-Willi Research (FPWR) 2026 Annual Research Symposium & Family Conference, taking place Oct. 7-10 in P…
View source ↗ - Newsprnewswire.com·7d ago·Neutral
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D. SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W.
View source ↗ - Newsmarketbeat.com·13d ago·Neutral
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit Neurocrine Biosciences NASDAQ: NBIX outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company's efforts to diversify beyond its largest product, INGREZZA.
View source ↗ - News (RSS)seekingalpha·20d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·25d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·33d ago·Neutral
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.
View source ↗ - Newszacks.com·41d ago·Negative
NBIX vs. TEVA: Which Drugmaker Is the Better Investment? Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
View source ↗ - News (RSS)seekingalpha·45d ago·Neutral
Neurocrine Biosciences: 'House Full Of Options'
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Neurocrine Biosciences: 'House Full Of Options' Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a deep, diversified pipeline. Ingrezza anchors NBIX's profitability, with exclusivity until 2038 and projected peak sales of $3.3B, while Crenessity and Vykat XR add growth pillars. Valuation models yield $224/share (DCF) and $167/share (with all research costs), both above recent market prices, highlighting undervaluation.
View source ↗ - Newszacks.com·46d ago·Positive
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
View source ↗ - Newszacks.com·46d ago·Positive
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
View source ↗ - Newszacks.com·46d ago·Positive
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.
View source ↗ - Newszacks.com·49d ago·Neutral
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.
View source ↗ - Newsprnewswire.com·55d ago·Neutral
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple validated patient-reported outcomes Mean improvements in the patien
View source ↗ - Newsreuters.com·55d ago·Negative
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Experts in Prader-Willi Syndrome on Tuesday raised safety concerns over Neurocrine's drug Vykat XR, citing serious adverse events reported in patients with the rare genetic disorder.
View source ↗
Earnings
Tue, Oct 27(in 3 weeks)
Consensus estimate $1.92 per share
Typical surprise +4.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.39 vs $1.65miss
- Tue, May 5$1.94 vs $1.22beat
- Wed, Feb 11$1.88 vs $1.80beat
- Tue, Oct 28$2.04 vs $1.58beat
- Wed, Jul 30$1.06 vs $0.98beat
- Mon, May 5$0.08 vs $0.54miss
Estimates and results for NBIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NBIX officers and directors.
- Bought
- —
- Sold
- $22.5m
0 trades
27 trades
- Boyer David W.sold
- Abernethy Mattsold
- Benevich Ericsold
- Norwalk Leslie Vsold
- Delaet Ingridsold
- Lippoldt Darinsold
- Delaet Ingridsold
- Delaet Ingridsold
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (63d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 18, 2024 (29d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 18, 2024 (23d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Nov 17, 2023 (21d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Nov 17, 2023 (21d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 20, 2023 (37d later)Buy$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 20, 2023 (37d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (51d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (51d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 20, 2023 (35d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 20, 2023 (35d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 27, 2022 (44d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 27, 2022 (37d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (41d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (41d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.